MedPath

Tagged News

Major Pharma Companies Form AI Consortium to Accelerate Drug Discovery Through Federated Data Sharing

AIDrug Discovery
  • Bristol Myers Squibb, Takeda Pharmaceuticals, and Astex Pharmaceuticals are joining an AI consortium with AbbVie and Johnson & Johnson to train the OpenFold3 drug discovery model.
  • The companies will contribute data from several thousand experimentally determined protein-small molecule structures using a federated sharing model that keeps sensitive data secure.
  • The initiative aims to improve OpenFold3's accuracy in predicting protein-small molecule interactions, enabling advances in small molecule discovery beyond what individual companies could achieve alone.
  • OpenFold3 represents the flagship project of the industry-led AI Structural Biology Network, developed in collaboration with Columbia University's AlQuraishi Lab.

Lunai Bioworks Completes Corporate Rebranding with Focus on AI-Powered Drug Discovery and Parkinson's Research

AIDrug Discovery
  • Lunai Bioworks Inc. (formerly Renovaro Inc.) officially adopted its new corporate identity on September 30, 2025, trading under ticker symbol "LNAI" following a 10:1 reverse stock split.
  • The company launched a proprietary transformer-based platform that embeds neurotoxicity intelligence into generative AI pipelines for safe compound discovery and biodefense applications.
  • Through subsidiary BioSymetrics Inc., Lunai advanced a preclinical biomarker discovery program in Parkinson's Disease using phenogrouping and multimodal data analysis.
  • BioSymetrics secured a multi-year STTR grant from NIH to support platform expansion and validation of their AI-driven therapeutic discovery capabilities.

BenchSci Partners with Thermo Fisher Scientific to Deploy AI-Powered Drug Discovery Tools

AIDrug Discovery
  • BenchSci announced a strategic partnership with Thermo Fisher Scientific to develop AI-powered research tools that accelerate experimental design and improve R&D productivity for life sciences researchers.
  • The collaboration will leverage BenchSci's ASCEND™ AI technology to create enterprise software solutions for scientific instruments, advanced literature search capabilities, and optimized reagent selection tools.
  • The partnership enables clients to use BenchSci's software to design experiments with Thermo Fisher equipment, analyze results, and feed data back into the system to guide future discoveries.
  • BenchSci's AI platform compiles data from academic publications, patent filings, clinical trials, and pharmaceutical clients' experiments, accessible through an AI chatbot interface for scientific inquiries.

Inflammatix Publishes Breakthrough Sepsis Research in Nature Medicine, Validates AI-Powered TriVerity Test

AIPrecision Medicine
  • Inflammatix published three landmark studies in Nature Medicine that redefine sepsis diagnosis and treatment through AI-powered immune profiling and consensus frameworks.
  • The SEPSIS-SHIELD study validated TriVerity's ability to distinguish bacterial from viral infections and predict illness severity in over 1,200 patients with high sensitivity and specificity.
  • Two new consensus frameworks, HI-DEF and CTS, identified distinct immunological states in sepsis patients, with dysregulated patients showing 5-7 times higher mortality risk.
  • TriVerity received FDA 510(k) clearance in January 2025 and delivers results in 30 minutes to guide emergency department triage decisions.

TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis

NCT04094818Completed
Inflammatix
Posted 2/28/2020

Aidoc Receives FDA Breakthrough Device Designation for Multi-Condition AI Triage System

AI
  • Aidoc has received FDA Breakthrough Device Designation for its novel multi-triage AI solution that flags multiple life-threatening conditions within a single workflow, marking the first-ever designation for AI with such broad medical coverage.
  • The system is powered by CARE, described as the first clinical-grade foundation model in healthcare with FDA cleared solutions, designed to help care teams attend to high-risk cases faster across health systems.
  • The designation enables parallel FDA review of multiple indications under a single submission, potentially accelerating access to comprehensive clinical AI while addressing critical bottlenecks in emergency departments where median visit times now exceed 160 minutes.

Predictive Oncology Secures $343.5 Million to Launch World's First Strategic Compute Reserve for AI Drug Discovery

AIDrug DiscoveryOncology
  • Predictive Oncology completed two private placement transactions totaling $343.5 million to establish the world's first Strategic Compute Reserve using ATH tokens from the Aethir ecosystem.
  • The company's AI platform PEDAL can predict with 92% accuracy if a tumor sample will respond to specific drug compounds, supported by a biobank of over 150,000 human tumor samples.
  • The strategic partnership with Aethir's decentralized GPU network provides 40-80% cost savings compared to traditional cloud providers, enhancing the company's computational capabilities for AI-driven drug discovery.
  • Former Cantor Fitzgerald CEO Shawn Matthews joined the board to support the digital asset treasury strategy, which aims to democratize access to AI infrastructure for cancer research.

Recursion Pharmaceuticals Advances AI-Powered Cancer Drug REC-617 to Phase 2 Trial Despite High-Risk Profile

AIDrug Discovery
  • Recursion Pharmaceuticals has advanced its lead cancer drug candidate REC-617, a novel CDK7 inhibitor, to phase 2 clinical trials with top-line results expected in 2028.
  • The company is applying artificial intelligence to drug discovery processes, with analysts projecting a potential 53% stock price increase despite the inherent risks of biotech development.
  • REC-617 could become the first cancer treatment of its kind if successful, though the majority of cancer drugs advancing from phase 1 to phase 2 trials never earn approval or generate sales.

Illumina Launches BioInsight AI Unit and Expands KRAS Companion Diagnostic Partnerships

AIDrug Discovery
  • Illumina launched BioInsight, a new AI-driven business unit focused on multiomic data analysis for drug discovery, with Rami Mehio as senior vice president and general manager.
  • The company secured multiple global pharmaceutical partnerships to advance its TruSight Oncology genomic profiling assay as a companion diagnostic targeting KRAS alterations.
  • This strategic shift represents Illumina's transition from sequencing hardware toward comprehensive AI-powered data analysis and deeper pharmaceutical collaborations.
  • Despite recent partnerships, the company faces ongoing challenges from U.S. research funding uncertainty and competitive pressures in the genomics market.

University of Miami Enrolls First Patients in Pivotal Trial Testing AI-Powered Spine Pain Diagnostic Technology

AI
  • UHealth-University of Miami Health System has enrolled the first two patients in Aclarion's pivotal CLARITY trial, testing Nociscan technology for chronic low back pain surgical outcomes.
  • The randomized 300-patient study evaluates whether Nociscan's MR spectroscopy and AI algorithms can improve spine surgery results by identifying painful disc sources.
  • The multi-center trial includes major medical institutions and aims to demonstrate clinical and economic value, with interim results expected in Q2 2026.

Lunai Bioworks Advances AI-Powered Parkinson's Biomarker Discovery Program for Strategic Pharma Partnerships

AIPrecision MedicineDrug Discovery
  • Lunai Bioworks has advanced its preclinical biomarker discovery program for Parkinson's Disease using its subsidiary BioSymetrics' proprietary Augusta Platform, positioning the initiative for strategic pharmaceutical partnerships.
  • The program leverages phenogrouping technology to identify distinct patient subtypes with greater precision, enabling targeted therapeutic development in a market affecting over 10 million people globally.
  • The company's approach has received validation through a competitive STTR grant from the National Institutes of Health and recognition from the Michael J. Fox Foundation.
  • With Parkinson's incidence expected to double by 2050, the expanding patient population represents a significant unmet medical need and compelling opportunity for therapeutic innovation.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.